Dysferlinopathies are a group of autosomal recessive muscular dystrophies caused by mutations in *DYSF*. There are 3 main phenotypes: Miyoshi muscular dystrophy 1 (MMD1; OMIM \#254130), limb-girdle muscular dystrophy type 2B (LGMD2B; OMIM \#253601), and distal myopathy with anterior tibial onset (OMIM \#606768). *DYSF* is located on chromosome 2p13.3-p13.1. It is composed of 55 exons coding for 2,080 amino acid residues, which form the dysferlin protein (approximately 230 kDa).^[@R1]^ Dysferlin is expressed in the plasma membrane of skeletal muscles^[@R2]^ and is involved in calcium-mediated membrane fusion events and membrane repair.^[@R3],[@R4]^ Patients with *DYSF* mutations have very low levels of dysferlin expression in skeletal muscle membranes (called primary dysferlinopathy).^[@R2],[@R5],[@R6]^ Secondary dysferlin deficiency or altered localization due to mutation of the non-*DYSF* gene has also been reported in patients with dystrophinopathy,^[@R7]^ sarcoglycanopathy,^[@R7]^ caveolinopathy,^[@R8][@R9][@R10]^ or calpainopathy^[@R8],[@R11][@R12][@R13]^ (often classified as secondary dysferlinopathy). Thus, the definitive diagnosis of dysferlinopathy requires identification of the *DYSF* mutation. Since 1998, our group has performed mutation analysis for *DYSF* in more than 160 families suspected of having dysferlinopathy using PCR--single-strand conformational polymorphism analysis or Sanger sequencing.^[@R1],[@R14],[@R15]^ We previously identified \>50 different mutations across the entire *DYSF* gene in approximately 60% of the patients.^[@R1],[@R14],[@R15]^ We did not find *DYSF* mutations in the remaining approximately 40% of the patients, which suggests that these patients may have mutations in other myopathy-associated genes.

The aim of this study was to conduct targeted next-generation sequencing of myopathy-associated genes to reanalyze the patients with suspected dysferlinopathy who did not previously show *DYSF* mutations. This should enable us to reveal the genetic profile for myopathies with dysferlin deficiency.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

This study was approved by the Ethics Committee of the Tohoku University School of Medicine, and all individuals gave their informed consent before their inclusion.

Patients. {#s1-2}
---------

### Cohort for targeted next-generation sequencing (cohort 1). {#s1-2-1}

PCR--single-strand conformational polymorphism analysis or Sanger sequencing of *DYSF* had previously been performed in 150 probands with suspected dysferlinopathy: 98 of them (65.3%) were diagnosed with *DYSF* mutations and 52 (34.7%) remained undiagnosed, with no pathogenic mutation in 43 and single heterozygous mutations in 9 (table e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000036)). A total of 64 patients, including the above-mentioned prescreened but undiagnosed 52 patients and 12 newly enrolled patients, were analyzed using targeted next-generation sequencing. Of the 64 patients analyzed, a deficiency or reduction in sarcolemmal dysferlin was confirmed in 41 patients using immunohistochemical analysis of dysferlin in muscle samples (classified as "pathologically proven cases"), whereas dysferlin deficiencies were not confirmed in the remaining 23 patients, mainly because muscle biopsies or immunohistochemical analyses for dysferlin had not been performed (classified as "clinically suspected cases") ([table 1](#T1){ref-type="table"}). All of the 23 patients had teenage-to-adult--onset slowly progressive myopathy without predominant cardiac dysfunction or early-onset respiratory dysfunction with at least 1 of the dysferlinopathy-likely phenotypes: initial or strong involvement of the flexor muscles in distal lower limbs (15 of 23 patients) or a moderate-to-extreme increase (\>1,000 IU/L) in serum creatine kinase (CK) levels (12 of 23 patients).

###### 

Constitution and results for 2 cohorts
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### Cohort for analyzing the genetic profile in the pathologically proven cases (cohort 2). {#s1-2-2}

To analyze the genetic profile in the pathologically proven cases, the 47 patients with previously identified *DYSF* mutations^[@R1],[@R14],[@R15]^ and the 2 patients with *CAPN3* and *CAV3*^[@R10]^ mutations were combined with the aforementioned 41 undiagnosed but pathologically proven cases, amounting to a total of 90 patients in this cohort ([table 1](#T1){ref-type="table"}).

Immunohistochemical analysis for dysferlin. {#s1-3}
-------------------------------------------

Immunohistochemical analysis for dysferlin in muscle samples was performed in the institution or hospital that the patient visited. Although the detailed methods may not have been identical in all cases, most cases were investigated by the avidin--biotin--peroxidase complex immunostaining method using the mouse monoclonal antibody to dysferlin (NCL-Hamlet; Leica Biosystems, Wetzlar, Germany) as the primary antibody.

Targeted next-generation sequencing. {#s1-4}
------------------------------------

We selected 42 genes that have been reported to cause adult-onset myopathy or muscular dystrophy ([table 2](#T2){ref-type="table"}). The targeted regions were designed using the SureDesign system (Agilent Technologies, Santa Clara, CA) to include all coding exons with 3′ and 5′ intronic 25-bp flanking bases (the regional source for coding exons was extracted from RefSeq, CCDS, Ensemble, Gencode, or Vega databases) and 3′ and 5′ untranslated regions. The targeted region for *DYSF* was designed to include 58 exons (i.e., exon 1--55, the alternative first exon, and exons 5a and 40a) to cover all alternative spliced variants. Of the total targeted region of 498.98 kb, 488.98 kb (98.08% coverage) was expected to be covered by 17,143 amplicons. Genomic DNA from the targeted region was captured using the HaloPlex target-enrichment system (Agilent Technologies). Targeted libraries were sequenced using the MiSeq platform, according to the manufacturer\'s instructions (Illumina, San Diego, CA). Paired 151-bp reads were aligned to the reference human genome (UCSChg19) using the Burrows--Wheeler Alignment tool.^[@R16]^ Single-nucleotide variants and indels were identified using the Genome Analysis Toolkit v1.5.^[@R17]^ Single-nucleotide variants and indels were annotated against the RefSeq and Single Nucleotide Polymorphism databases (dbSNP137) in the ANNOVAR program.^[@R18]^ We used the PolyPhen-2 polymorphism phenotyping software tool and SIFT^[@R19],[@R20]^ to predict the functional effects of mutations and eXome-Hidden Markov Model (XHMM, <http://atgu.mgh.harvard.edu/xhmm/>) to call copy-number variations. We extracted variations that were listed as myopathy-causing mutations in the Human Gene Mutation Database (HGMD; provided by BIOBASE, Waltham, MA). For further analysis, we filtered variations satisfying all of the following conditions: variations located in exon or splice sites that were not detected in the control DNA included in the HaloPlex target enrichment system, variations that were covered by a minimum of 20 reads with a genotype quality score of at least 80, and variations with an altered allele frequency that ranged from 0.3 to 0.7 in the heterozygous state or that was greater than 0.7 in the homozygous state. Among these, nonsynonymous variants that either were absent or had a frequency of \<1% in both the 1000 Genomes Database and the Human Genetic Variation Database (<http://www.genome.med.kyoto-u.ac.jp/SnpDB/>) were left as rare variants.
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The 42 myopathy-associated genes targeted in this study
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Sanger sequencing. {#s1-5}
------------------

We performed Sanger sequencing to confirm that the mutations identified by exome sequencing segregated with the disease. PCR products were purified using a MultiScreen-PCR plate (Millipore, Billerica, MA) followed by sequencing with a 3500xL Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA).

Multiplex ligation-dependent probe amplification. {#s1-6}
-------------------------------------------------

To investigate copy-number variation in *DYSF*, we performed multiplex ligation-dependent probe amplification (MLPA) with SALSA MLPA probemix P268-A1 DYSF (MRC Holland, Amsterdam, the Netherlands) according to the manufacturer\'s instructions. This MLPA design contains probes to amplify 40 of the 58 exons. Genomic DNA (50--250 ng) was hybridized using the probemix. After ligation and amplification, the PCR products were separated by size using a 3130xL Genetic Analyzer (Thermo Fisher Scientific). Relative peak areas were calculated with GeneMapper software (Thermo Fisher Scientific).

Subcloning. {#s1-7}
-----------

To investigate the allelic condition of multiple heterozygous mutations in a particular gene, we performed subcloning of PCR products. Long-range PCR was performed under optimized long-PCR conditions using LA Taq polymerase (Takara, Shiga, Japan). The PCR products were subcloned into the vector pCR2.1 TOPO (Invitrogen, Waltham, MA). Several clones were randomly picked from each bacterial culture, and DNA was extracted for Sanger sequencing.

RESULTS {#s2}
=======

Targeted next-generation sequencing. {#s2-1}
------------------------------------

An average of 96.8% (92.6%--98.2%) and 93.7% (84.6%--97.6%) of the overall targeted regions had at least 10- and 30-fold coverage, respectively (table e-2). The average read depth calculated for each gene ranged from 207 (*GFPT1*) to 429 (*CAV3*). An average of 89.7% (*FKRP*) to 99.9% (*CAPN3*) of the targeted regions had at least 10-fold coverage, and 83.1% (*FKRP*) to 99.4% (*TRIM32*) of the targeted regions had at least 30-fold coverage. These regions corresponded to those estimated to have been uncaptured by any amplicon. The sequencing data covered 99.4% and 98.1% of the targeted *DYSF* region with at least 10- and 30-fold coverage, respectively, with an average read depth of 388.

With reference to the HGMD, 0--3 myopathy-causing mutations were extracted per individual. After filtering with the quality-related and frequency thresholds described earlier, 0--17 rare nonsynonymous variants remained per individual. After considering the predicted functional effect, pattern of inheritance, and clinical information, putative pathogenic variants were detected in 38 of 64 patients (26 of 52 prescreened undiagnosed patients and all 12 newly enrolled patients).

Twenty-three of the 38 mutation-positive patients (12 of 52 prescreened undiagnosed patients and 11 of 12 newly enrolled patients) had *DYSF* mutations; these included 6 novel mutations ([tables 1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}). Novel homozygous deletion of exons 37 and 38 (Dys194-1) and heterozygous deletion of exons 37 to 41 (Dys119-1-2) were predicted by XHMM software and confirmed by MLPA and Sanger sequencing, which revealed deletions of 5,862 and 51,161 bps, respectively.

###### 

Summary of known or putative pathogenic *DYSF* mutations detected in this study
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The remaining 16 patients (15 of 52 prescreened undiagnosed patients and 1 of 12 newly enrolled patients), including a single patient (Dys149-1) in whom the *DYSF* mutation was simultaneously detected, were revealed to harbor known or rare mutations in non-*DYSF* genes ([tables 1](#T1){ref-type="table"} and [4](#T4){ref-type="table"}). Of these, novel or known mutations in *CAPN3* were detected in 10 patients, accounting for the majority of non-*DYSF* genes. The heterozygous p.V805A mutation in *MYH2*, which is a known mutation leading to inclusion body myositis,^[@R21]^ was detected in Dys86-1. The pathogenicity of this mutation remained uncertain because of the lack of relevant information in muscle pathology.

###### 

Summary of known or putative pathogenic non-*DYSF* mutations detected in this study
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Subsequently, MLPA was performed for the remaining 27 patients (table e-1), including all 14 patients who were undiagnosed after targeted sequencing but were pathologically proven, through targeted next-generation sequencing. We detected no additional duplications or deletions in *DYSF* (table e-1).

Genetic profile for pathologically proven cases. {#s2-2}
------------------------------------------------

[Figure 1](#F1){ref-type="fig"} shows the genetic profile of the 90 pathologically proven cases (patients who showed sarcolemmal dysferlin deficiency in immunohistochemical analyses). Intriguingly, the 63 patients (47 previously diagnosed patients and 16 newly diagnosed patients) with *DYSF* mutations accounted for only 70% of cases, *CAPN* mutations accounted for 10% of cases (9/90), and *CAV3* mutations accounted for 2% of cases (2/90). The other genetic profile included mutations in *ANO5*, *GNE*, and *MYOT* (together with *CAV3* and *DYSF*), each of which was detected in a single individual. Clinical information for the remaining 14 patients who showed secondary dysferlin deficiency due to putative pathogenic mutations in non-*DSYF* genes is summarized in [table 5](#T5){ref-type="table"}.

![Genetic profile of 90 patients with dysferlin deficiency\
*DYSF* mutations were identified in a total of 63 patients (70%). Nine patients (10%) were diagnosed with *CAPN3* mutations. Of the 90 patients, 38 and 41 manifested as distal myopathy (DM) and limb-girdle muscular dystrophy (LGMD), respectively, and the remaining 11 were unclassifiable. The genetic profiles for each manifestation are also shown. The proportion of *DYSF* mutations was more frequent for the DM phenotype (76%) than for the LGMD phenotype (63%), whereas *CAPN3* mutations were more frequent in the LGMD phenotype (15%) than in the DM phenotype (5%).](NG2015001057FF1){#F1}
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Clinical characteristics for the 14 patients who showed secondary dysferlin deficiency
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DISCUSSION {#s3}
==========

We performed targeted next-generation sequencing of 42 myopathy-associated genes in 64 patients with clinically or pathologically suspected dysferlinopathy. We found possible pathogenic mutations in *DYSF* or other genes in 38 patients (59.4%). The use of this targeted resequencing technique improved positive genetic detection from 65.3% (98/150 patients) to 82.7% (124/150 patients) overall, owing to (1) the detection of previously unrevealed *DYSF* mutations, including gross deletions, and (2) the comprehensive sequencing of non-*DYSF* genes and the detection of novel or known mutations in these genes.

Although secondary dysferlin deficiency can be caused by *CAPN3* mutations,^[@R11][@R12][@R13]^ the exact frequency of *CAPN3* mutations in patients with dysferlin deficiency has not been reported previously. Human *CAPN3* is located on chromosome 15q15.1-15.3, comprises 24 exons, and codes a Ca^2+^-dependent cysteine protease called calpain 3 (p94). Across the entire *CAPN3* gene, nearly 300 mutations have been reported to be pathogenic and the cause of LGMD2A (OMIM \#253600),^[@R22]^ which is estimated to be the most frequent type of LGMD in the Japanese population.^[@R8]^ In this study, although mutations in *CAPN3* were essentially distributed sporadically, thus not suggesting a specific genotype to associate with dysferlin deficiency, our result of 10% frequency in *CAPN3* mutations with dysferlin deficiency emphasizes the necessity for genetic analysis of both genes.

Clinically, 2 of the 9 patients with *CAPN3* mutations manifested atypically with a distal myopathy (DM) phenotype rather than LGMD ([figure 1](#F1){ref-type="fig"}, [table 5](#T5){ref-type="table"}). One of the patients with DM (Dys189-1) had weakness of the tibialis anterior muscle as an initial symptom and showed gastrocnemius muscle atrophy, closely resembling MMD1 ([table 5](#T5){ref-type="table"}).

Immunohistochemistry for calpain 3 revealed reduced expression in this patient. The other patient (Dys88-1) also had distal weakness with wasting, particularly in the tibialis anterior muscle. Although immunohistochemistry for calpain 3 was rarely investigated in our cases of dysferlinopathy, a secondary reduction in calpain 3 with *DYSF* mutations has also been reported.^[@R23]^ These findings indicate that it is difficult to distinguish calpainopathy from dysferlinopathy, even when considering clinical information together with immunohistochemical analysis of both proteins. Genetic analysis of both genes would be valuable for genetic counseling, clinical management,^[@R24]^ and possible specific genetic therapies in the future.

Non-*DYSF* and non-*CAPN3* genes were responsible for 5% of patients with dysferlin deficiencies ([figure 1](#F1){ref-type="fig"}, [table 5](#T5){ref-type="table"}). A novel *CAV3* mutation was identified in Dys203-1, and immunohistochemical analyses in this patient showed reduced expression of both dysferlin and caveolin, confirming the diagnosis. Together with the known homozygous p.L556P mutation in *DYSF*, a known heterozygous p.R405K mutation in *MYOT* and a rare mutation of p.V14I in *CAV3* were detected in 1 patient (Dys149-1). This patient was a sporadic case with isolated hyperCKemia. Thus, it is unknown whether the muscle pathology showing absent dysferlin was caused by the *DYSF* mutation or by the associated effects of multiple mutations. A novel homozygous *ANO5* splicing mutation was identified in Dys201-1. *ANO5* encodes the transmembrane protein anoctamin 5 and is the causative gene for MMD3 (OMIM \#613319) and LGMD2L (OMIM \#611307). Asymmetrical muscle atrophy was predominantly observed in the gastrocnemius, biceps femoris, and adductor magnus in this patient and is a possible distribution in both MMD1 and MMD3.^[@R25]^ Expression of dysferlin in this patient was diffusely decreased, mimicking MMD1 (figure e-1). A homozygous *GNE* mutation was detected in Dys91-1, compatible with DM with rimmed vacuoles, and this patient had a partial reduction in dysferlin (figure e-1). Secondary dysferlin deficiency from mutations in *ANO5* or *GNE* has not been reported previously. Hence, further investigations are required to clarify the possible association between these mutations and dysferlin deficiency.

Even after the targeted next-generation sequencing, 26 of 64 patients (40.6%) remained undiagnosed. This means that undiagnosed patients accounted for 15.6% of pathologically proven cases (14/90 patients) and 16.2% of clinically suspected cases (12/74 patients), showing nonsignificant difference between the 2 groups ([table 1](#T1){ref-type="table"}). There are several possible explanations: (1) mutations in subtle unsequenced targeted regions were not detected in this study; (2) intronic *DYSF* mutations that might result in abnormal splicing were not detected because these regions, along with messenger RNA, were not investigated; (3) pathogenic mutations were excluded because of biased filtering or overfiltering; or, most probably; (4) other genes not targeted in this study may be responsible. More than 50 molecules have been reported to interact with dysferlin.^[@R26][@R27][@R32]^ These molecules are encoded by a fraction of genes such as *CAPN3*, *CAV3*, *DES*, *FLNC*, and *FHL1*, which are already known to cause myopathies. The remaining molecules may well be the next candidates. The identification of novel molecules that cause dysferlin deficiency can help elucidate the mechanisms by which dysferlin achieves membrane repair.

The study had a few limitations. The targeted genes in this study did not include the *DMD* gene, whose mutation is reported to result in secondary dysferlinopathy.^[@R7]^ The immunoblot assay of muscle samples was not performed because muscle samples were not available. Thus, the quantitative level of dysferlin expression in sarcolemma or cytoplasm remains undetermined. The allelic zygosity of the multiple heterozygous candidate variants was not confirmed in all patients for the following reasons: (1) long-range PCR was unsuccessful if the distance between variants was too long or genomic DNA was estimated to be fragmented, or (2) there was a lack of available genomic parental DNA.

We used targeted next-generation sequencing to effectively and comprehensively analyze mutations in myopathy-associated genes and to clarify the heterogeneous nature of the genetic profile in patients with suspected dysferlinopathy. Our results illustrate the importance of comprehensive analysis of related genes when performing genetic diagnosis for dysferlinopathy. We believe that the genes and molecules responsible for the cases in which diagnosis remained unresolved will be identified by future whole-exome sequencing projects.
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